02/28/2008- Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 01/03/2008- Pharmos Corporation Announces Board and Management Changes Robert F. Johnston Named Executive Chairman of the Board S. Colin Neill Named President 01/03/2008- Pharmos Corporation Completes Initial Closing of Private Placement 12/18/2007- Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company 12/10/2007- Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference 11/01/2007- Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 10/30/2007- Pharmos Corporation Reports 2007 Third Quarter Results 10/30/2007- Pharmos Restructures Operations in Israel 09/28/2007- Pharmos Receives Notice Related to Nasdaq Minimum Bid Price Rule 09/10/2007- Pharmos Issues Letter to Shareholders 08/08/2007- Pharmos Corporation Reports 2007 Second Quarter Results Restructuring and Cost Reduction Plan Implemented in Early August 2007 06/27/2007- Pharmos Commences Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 06/20/2007- Pharmos Commences Phase 2b Irritable Bowel Syndrome Study 06/07/2007- Pharmos Corporation Announces Settlement of Class Action Litigation 05/10/2007- Pharmos Corporation Reports 2007 First Quarter Results 05/08/2007- Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference 04/24/2007- Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Nociceptive Pain in Third Molar Dental Extraction Model 03/29/2007- Pharmos Receives $1.5 Million Grant 03/15/2007- Pharmos Corporation Reports 2006 Year-end and Fourth Quarter Results 02/26/2007- Pharmos Announces Appointment of Elkan Gamzu as New Chief Executive Officer 01/19/2007- Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain 12/14/2006- Pharmos Completes Preclinical Toxicology and Safety Pharmacology Studies in Oral Cannabinor 12/11/2006- Pharmos Corporation to Present at the 2006 RBC Capital Markets Healthcare Conference 12/05/2006- SCHEDULE CHANGE: Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference at 10:30 AM Eastern Time on December 7, 2006 11/30/2006- Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference 11/14/2006- Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion Cream 11/06/2006- Pharmos Corporation Reports 2006 Third Quarter Results 10/26/2006- Pharmos Corporation to Present at the C.E. Unterberg Towbin Life Sciences Conference 10/25/2006- Pharmos Shareholders Approve Vela Pharmaceuticals Transaction 10/05/2006- Pharmos Appoints S. Colin Neill as CFO 09/05/2006- Pharmos and Vela Revise Transaction Terms 08/10/2006- Pharmos Corporation Reports 2006 Second Quarter Results 08/10/2006- Pharmos Commences Dosing in Second Phase 2a Study of Cannabinor in Experimentally Induced Pain 07/12/2006- Pharmos Expands Corporate Website and Adds Hebrew Language Site Authorities 06/29/2006- Pharmos Commences Patient Dosing in Phase 2a Cannabinor Nociceptive Pain Study 06/20/2006- Pharmos Phase 2a Cannabinor Study to Evaluate Analgesic Activity and Safety in Acute Pain Approved by UK Regulatory Authorities 05/19/2006- Pharmos Corporation Engages Burrill & Company for Business Development Initiatives 05/11/2006- Pharmos Corporation to Present at the Rodman & Renshaw Third Annual Global Healthcare Conference 05/09/2006- Pharmos Corporation Reports 2006 First Quarter Results 04/10/2006- Pharmos Receives Grant from Israel Government 04/05/2006- Pharmos Sets Strategic Priorities for Development of Vela Compounds 03/17/2006- U.S. Congressman Mike Ferguson (R-NJ) Will Tour Pharmos Facility 03/15/2006- Pharmos Agrees to Acquire Vela Pharmaceuticals Inc. 03/15/2006- Pharmos Corporation Reports 2005 Fourth Quarter and Year-end Results 01/26/2006- Pharmos Completes Phase I Cannabinor Study 11/7/2005- Senior Pharmaceutical Executive Joins Pharmos Management 11/3/2005- Pharmos Corporation Reports 2005 Third Quarter Results 10/27/2005- Pharmos Corporation to Present at the 7th Annual Rodman & Renshaw Techvest Healthcare Conference 10/17/2005- Pharmos to Present at the 2005 BIO Investor Forum 9/21/2005- Pharmos Announces Shareholder Approval of All Proxy Proposals at Regularly Scheduled Annual General Meeting 9/6/2005- Pharmos Initiates Phase I Trial of CB2-Selective Drug Candidate Cannabinor 7/28/2005- Pharmos Corporation Reports 2005 Second Quarter Results 7/6/2005- Pharmos to Initiate Clinical Program in Tissue-directed Treatment of Inflammation and Pain 6/28/2005- Dr. Abraham Sartani Appointed to Pharmos Board 6/16/2005- Pharmos to Present at the BIO 2005 Business Forum 6/6/2005- Forum Alert: Pharmos Corporation will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum 5/31/2005- Pharmos Announces Reverse Split of Common Stock 5/23/2005- Pharmos Corporation to Present at the Bio-Tech Israel 2005 Conference 5/3/2005- Pharmos Receives Grant from Israel Government 4/28/2005- Pharmos Corporation Reports 2005 First Quarter Results 4/20/2005- Pharmos Corporation Strengthens Management Team to Support Pipeline Development 3/9/2005- Pharmos Corporation Reports 2004 Results 2/28/2005- Pharmos Announces Conference Call for Q4 and FY2004 Financial Results and Comments on Pipeline Status 1/25/2005- Pharmos Receives Milestone Payment From Bausch & Lomb for Zylet™ Commercial Launch

More News:

<< 2003 News >>        << 2002 News >>         << 2001 News >>